3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Multiple Myeloma
7
Pain, Postoperative
5
Pain
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Burkitt Lymphoma
3
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lung Neoplasms
2
Leukemia, Hairy Cell
2
Hodgkin Disease
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma in Situ
2
Breast Neoplasms
2
Agnosia
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Papillomavirus Infections
1
Ovarian Neoplasms
1
Interventions
Paclitaxel
69
Bevacizumab
62
Carboplatin
53
pembrolizumab
46
olaparib
32
Specimen Handling
27
Gemcitabine
27
Cyclophosphamide
26
Magnetic Resonance Spectroscopy
24
liposomal doxorubicin
22
Cisplatin
21
niraparib
20
Taxes
18
Nivolumab
18
fludarabine
17
Topotecan
17
Biopsy
17
Doxorubicin
14
Immunoglobulin G
12
Fulvestrant
12
Disulfides
12
Oxaliplatin
10
mirvetuximab soravtansine
9
durvalumab
9
aldesleukin
9
Surveys and Questionnaires
9
Ipilimumab
9
Fluorouracil
9
Blood Specimen Collection
9
cemiplimab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Acetaminophen
×
1 year
×
Clear all
NCT06824467
2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled